ArticleBMC medical research methodology2022
Stacked survival models for residual lifetime data.
Article in BMC medical research methodology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A novel non-negative Bayesian stacking modeling method for Cancer survival prediction using high-dimensional omics data.BMC medical research methodology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
When modelling the survival distribution of a disease for which the symptomatic progression of the associated condition is insidious, it is not always clear how to measure the failure/censoring times from some true date of disease onset. In a prevalent cohort study with follow-up, one approach for removing any potential influence from the uncertainty in the measurement of the true onset dates is through the utilization of only the residual lifetimes. As the residual lifetimes are measured from a well-defined screening date (prevalence day) to failure/censoring, these observed time durations are essentially error free. Using residual lifetime data, the nonparametric maximum likelihood estimator (NPMLE) may be used to estimate the underlying survival function. However, the resulting estimator can yield exceptionally wide confidence intervals. Alternatively, while parametric maximum likelihood estimation can yield narrower confidence intervals, it may not be robust to model misspecification. Using only right-censored residual lifetime data, we propose a stacking procedure to overcome the non-robustness of model misspecification; our proposed estimator comprises a linear combination of individual nonparametric/parametric survival function estimators, with optimal stacking weights obtained by minimizing a Brier Score loss function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.